Travis Criteria for Severe Ulcerative Colitis
Predicts response to IV corticosteroids in acute severe ulcerative colitis (ASUC). The Oxford criteria identify patients who may need ciclosporin or urgent colectomy by day 3.
Score interpretation
Stool frequency ≤3/day + CRP ≤45 mg/L on day 3 — likely steroid responder
→ Continue IV hydrocortisone; reassess at day 5–7; oral prednisolone if improving
Intermediate response — closely monitor by day 5
→ Re-evaluate on day 5; if no improvement, consider ciclosporin or infliximab rescue
Stools >8/day OR stools 3–8/day with CRP >45 mg/L — 85% probability of colectomy
→ Urgent colorectal surgery review; initiate ciclosporin or infliximab rescue therapy; nil by mouth; surgical consent
Interpretation bands for the Travis Criteria. Apply clinical judgement and local guidance.
References
- Travis SP et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38(6):905–910.
Related
Curated clinical cross-links plus same-class fallbacks.
- Harvey-Bradshaw Index for Crohn's Disease · Inflammatory Bowel Disease
- Mayo Score for Ulcerative Colitis Activity · Inflammatory Bowel Disease
- Crohn's Disease Activity Index (CDAI) · Inflammatory Bowel Disease
- Truelove and Witts Severity Index for Ulcerative Colitis · Inflammatory Bowel Disease
- Ulcerative Colitis Endoscopic Index of Severity (UCEIS) · Inflammatory Bowel Disease
- Simplified Endoscopic Score for Crohn's Disease (SES-CD) · Inflammatory Bowel Disease
- Dimethyl Fumarate · Disease-Modifying Therapy — Relapsing-Remitting Multiple Sclerosis
- Natalizumab · Disease-Modifying Therapy — MS (Anti-VLA-4 Monoclonal Antibody)
- Interferon Beta-1a · Disease-Modifying Therapy — MS (Interferon)
- Apomorphine · Dopamine Agonist — Parkinson's Disease Rescue / Continuous Infusion
- Ocrelizumab · Multiple Sclerosis — Disease-Modifying Therapy
- Fingolimod · Multiple Sclerosis — Disease-Modifying Therapy
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.